Nana Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nana Li has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Haibing Wang
Department of Clinical Laboratory, Harbin Medical University Cancer Hospital, Harbin, China
1 shared publication - Jing Wang
Department of Clinical Laboratory, Harbin Medical University Cancer Hospital, Harbin, China
1 shared publication - Lichen Teng
Department of Clinical Laboratory, Harbin Medical University Cancer Hospital, Harbin, China
1 shared publication - Ling Guo
Department of Clinical Laboratory, Harbin Medical University Cancer Hospital, Harbin, China
1 shared publication - Ming Yu
Department of Clinical Laboratory, Harbin Medical University Cancer Hospital, Harbin, China
1 shared publication - Peihua Yan
Department of Clinical Laboratory, Harbin Medical University Cancer Hospital, Harbin, China
1 shared publication
Latest Publications
- Open Access
- 8 November 2025
- Published by Springer Nature in Medical Oncology
- Vol. 42 (12) , 1-13
Tβ4–17 peptide enhances the chemo-sensitivity of ovarian cancer cells to DDP by affecting NF-κB signaling pathway
Ovarian cancer is a gynecologic malignancy with high mortality and poor prognosis. Chemoresistance is a key cause of ovarian cancer recurrence and metastasis. It has been found that some bioactive peptides can inhibit the growth and metastasis of cancer cells and promote cell apoptosis, thus exerting anti-cancer effects. Tβ4–17 is a small polypeptide that we selected using ITRAQ technology, and its precursor protein is thymosin β4. This study mainly investigated its effect in combination with cisplatin (DDP) on the proliferation, migration and apoptosis of ovarian cancer resistant cells and related molecular mechanisms. Our results showed that Tβ4–17 peptide combined with DDP significantly inhibited the proliferation and migration of drug resistance cells in ovarian cancer, promoted apoptosis, and increased the chemo-sensitivity of ovarian cancer cells to DDP. In addition, qRT-PCR and Western blot showed that NF-κB was significantly highly expressed in DDP-resistant cells of ovarian cancer. After application of NF-κB inhibitors and activators, Western blot, CCK8, EDU fluorescence proliferation assay, and cell scratch assay showed that Tβ4–17 peptide down-regulated NF-κB p65 protein expression and inhibited cell proliferation and migration. In conclusion, our study demonstrates that Tβ4–17 peptide enhances the sensitivity of ovarian cancer cells to DDP by down-regulating NF-κB expression.
- 8 November 2025
- Published by Springer Nature in Medical Oncology
- Vol. 42 (12) , 1-13
Open AccessTβ4–17 peptide enhances the chemo-sensitivity of ovarian cancer cells to DDP by affecting NF-κB signaling pathway
Ovarian cancer is a gynecologic malignancy with high mortality and poor prognosis. Chemoresistance is a key cause of ovarian cancer recurrence and metastasis. It has been found that some bioactive peptides can inhibit the growth and metastasis of cancer cells and promote cell apoptosis, thus exerting anti-cancer effects. Tβ4–17 is a small polypeptide that we selected using ITRAQ technology, and its precursor protein is thymosin β4. This study mainly investigated its effect in combination with cisplatin (DDP) on the proliferation, migration and apoptosis of ovarian cancer resistant cells and related molecular mechanisms. Our results showed that Tβ4–17 peptide combined with DDP significantly inhibited the proliferation and migration of drug resistance cells in ovarian cancer, promoted apoptosis, and increased the chemo-sensitivity of ovarian cancer cells to DDP. In addition, qRT-PCR and Western blot showed that NF-κB was significantly highly expressed in DDP-resistant cells of ovarian cancer. After application of NF-κB inhibitors and activators, Western blot, CCK8, EDU fluorescence proliferation assay, and cell scratch assay showed that Tβ4–17 peptide down-regulated NF-κB p65 protein expression and inhibited cell proliferation and migration. In conclusion, our study demonstrates that Tβ4–17 peptide enhances the sensitivity of ovarian cancer cells to DDP by down-regulating NF-κB expression.